In a prospective longitudinal trial, researchers assessed the association between academic readiness and outcomes in patients who received brain tumor treatment in early childhood.

Ravi B Parikh, MD, MPP discusses the current and future use of artificial intelligence (AI) in the greater US health care ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities, according to a study published online Oct. 29 in the ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

The median progression-free survival was 12.5 months in the treatment-naïve cohort and 5.5 months in the previously treated cohort. The researchers evaluated capmatinib in the phase 2 GEOMETRY mono-1 ...

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

Researchers sought to determine whether combination decitabine, venetoclax, and ponatinib would be effective in patients with accelerated phase CML.

Improved three-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen. HealthDay News — For patients with operative triple-negative breast cancer, a multigene ...

Higher peak doses were associated with inferior progression-free survival and overall survival. Cancer patients may fare better if they receive lower corticosteroid doses to treat immune-related ...

Researchers sought to determine whether a low dose of bosutinib followed by escalation would be effective for patients with CML.

Higher Healthy Eating Index score linked to significantly lower risk for grade reclassification in men undergoing active surveillance.